Epigenetic age acceleration and metabolic syndrome in the coronary artery risk development in young adults study

Drew R. Nannini*, Brian T. Joyce, Yinan Zheng, Tao Gao, Lei Liu, Grace Yoon, Tianxiao Huan, Jiantao Ma, David R. Jacobs, John T. Wilkins, Jim Ren, Kai Zhang, Sadiya S. Khan, Norrina Bai Allen, Steve Horvath, Donald M. Lloyd-Jones, Philip Greenland, Lifang Hou

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background: The metabolic syndrome (MetS) is a collection of metabolic disturbances that can lead to various cardiovascular diseases. Previous studies have shown a more adverse metabolic risk profile is associated with more advanced biological aging. The associations between epigenetic biomarkers of age with MetS, however, are not well understood. We therefore investigated the associations between epigenetic age acceleration and MetS severity score and incident MetS. Results: A subset of study participants with available whole blood at examination years 15 and 20 from the Coronary Artery Risk Development in Young Adults Study underwent epigenomic profiling using the Illumina MethylationEPIC Beadchip (~ 850,000 sites). Intrinsic and extrinsic epigenetic age acceleration (IEAA and EEAA) were calculated from DNA methylation levels. The MetS severity score was positively associated with IEAA at years 15 (P = 0.016) and 20 (P = 0.016) and EEAA at year 20 (P = 0.040) in cross-sectional analysis. IEAA at year 20 was significantly associated with incident MetS at year 30 (OR = 1.05 [95% CI 1.01, 1.10], P = 0.028). Conclusions: To our knowledge, this is the first report of the longitudinal association between epigenetic age acceleration and MetS. These findings suggest that a higher MetS severity score is associated with accelerated epigenetic aging and such aging may play a role in the development of metabolic disorders, potentially serving as a useful biomarker of and early detection tool for future MetS.

Original languageEnglish (US)
Article number160
JournalClinical Epigenetics
Volume11
Issue number1
DOIs
StatePublished - Nov 15 2019

Fingerprint

Epigenomics
Young Adult
Coronary Vessels
Biomarkers
Metabolome
DNA Methylation
Cardiovascular Diseases
Cross-Sectional Studies

Keywords

  • CARDIA
  • DNA methylation
  • Epigenetic age acceleration
  • Metabolic syndrome

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Developmental Biology
  • Genetics(clinical)

Cite this

@article{1e517dda3ff14a8297e51c0a44e1c301,
title = "Epigenetic age acceleration and metabolic syndrome in the coronary artery risk development in young adults study",
abstract = "Background: The metabolic syndrome (MetS) is a collection of metabolic disturbances that can lead to various cardiovascular diseases. Previous studies have shown a more adverse metabolic risk profile is associated with more advanced biological aging. The associations between epigenetic biomarkers of age with MetS, however, are not well understood. We therefore investigated the associations between epigenetic age acceleration and MetS severity score and incident MetS. Results: A subset of study participants with available whole blood at examination years 15 and 20 from the Coronary Artery Risk Development in Young Adults Study underwent epigenomic profiling using the Illumina MethylationEPIC Beadchip (~ 850,000 sites). Intrinsic and extrinsic epigenetic age acceleration (IEAA and EEAA) were calculated from DNA methylation levels. The MetS severity score was positively associated with IEAA at years 15 (P = 0.016) and 20 (P = 0.016) and EEAA at year 20 (P = 0.040) in cross-sectional analysis. IEAA at year 20 was significantly associated with incident MetS at year 30 (OR = 1.05 [95{\%} CI 1.01, 1.10], P = 0.028). Conclusions: To our knowledge, this is the first report of the longitudinal association between epigenetic age acceleration and MetS. These findings suggest that a higher MetS severity score is associated with accelerated epigenetic aging and such aging may play a role in the development of metabolic disorders, potentially serving as a useful biomarker of and early detection tool for future MetS.",
keywords = "CARDIA, DNA methylation, Epigenetic age acceleration, Metabolic syndrome",
author = "Nannini, {Drew R.} and Joyce, {Brian T.} and Yinan Zheng and Tao Gao and Lei Liu and Grace Yoon and Tianxiao Huan and Jiantao Ma and Jacobs, {David R.} and Wilkins, {John T.} and Jim Ren and Kai Zhang and Khan, {Sadiya S.} and Allen, {Norrina Bai} and Steve Horvath and Lloyd-Jones, {Donald M.} and Philip Greenland and Lifang Hou",
year = "2019",
month = "11",
day = "15",
doi = "10.1186/s13148-019-0767-1",
language = "English (US)",
volume = "11",
journal = "Clinical Epigenetics",
issn = "1868-7075",
publisher = "Springer Verlag",
number = "1",

}

Epigenetic age acceleration and metabolic syndrome in the coronary artery risk development in young adults study. / Nannini, Drew R.; Joyce, Brian T.; Zheng, Yinan; Gao, Tao; Liu, Lei; Yoon, Grace; Huan, Tianxiao; Ma, Jiantao; Jacobs, David R.; Wilkins, John T.; Ren, Jim; Zhang, Kai; Khan, Sadiya S.; Allen, Norrina Bai; Horvath, Steve; Lloyd-Jones, Donald M.; Greenland, Philip; Hou, Lifang.

In: Clinical Epigenetics, Vol. 11, No. 1, 160, 15.11.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Epigenetic age acceleration and metabolic syndrome in the coronary artery risk development in young adults study

AU - Nannini, Drew R.

AU - Joyce, Brian T.

AU - Zheng, Yinan

AU - Gao, Tao

AU - Liu, Lei

AU - Yoon, Grace

AU - Huan, Tianxiao

AU - Ma, Jiantao

AU - Jacobs, David R.

AU - Wilkins, John T.

AU - Ren, Jim

AU - Zhang, Kai

AU - Khan, Sadiya S.

AU - Allen, Norrina Bai

AU - Horvath, Steve

AU - Lloyd-Jones, Donald M.

AU - Greenland, Philip

AU - Hou, Lifang

PY - 2019/11/15

Y1 - 2019/11/15

N2 - Background: The metabolic syndrome (MetS) is a collection of metabolic disturbances that can lead to various cardiovascular diseases. Previous studies have shown a more adverse metabolic risk profile is associated with more advanced biological aging. The associations between epigenetic biomarkers of age with MetS, however, are not well understood. We therefore investigated the associations between epigenetic age acceleration and MetS severity score and incident MetS. Results: A subset of study participants with available whole blood at examination years 15 and 20 from the Coronary Artery Risk Development in Young Adults Study underwent epigenomic profiling using the Illumina MethylationEPIC Beadchip (~ 850,000 sites). Intrinsic and extrinsic epigenetic age acceleration (IEAA and EEAA) were calculated from DNA methylation levels. The MetS severity score was positively associated with IEAA at years 15 (P = 0.016) and 20 (P = 0.016) and EEAA at year 20 (P = 0.040) in cross-sectional analysis. IEAA at year 20 was significantly associated with incident MetS at year 30 (OR = 1.05 [95% CI 1.01, 1.10], P = 0.028). Conclusions: To our knowledge, this is the first report of the longitudinal association between epigenetic age acceleration and MetS. These findings suggest that a higher MetS severity score is associated with accelerated epigenetic aging and such aging may play a role in the development of metabolic disorders, potentially serving as a useful biomarker of and early detection tool for future MetS.

AB - Background: The metabolic syndrome (MetS) is a collection of metabolic disturbances that can lead to various cardiovascular diseases. Previous studies have shown a more adverse metabolic risk profile is associated with more advanced biological aging. The associations between epigenetic biomarkers of age with MetS, however, are not well understood. We therefore investigated the associations between epigenetic age acceleration and MetS severity score and incident MetS. Results: A subset of study participants with available whole blood at examination years 15 and 20 from the Coronary Artery Risk Development in Young Adults Study underwent epigenomic profiling using the Illumina MethylationEPIC Beadchip (~ 850,000 sites). Intrinsic and extrinsic epigenetic age acceleration (IEAA and EEAA) were calculated from DNA methylation levels. The MetS severity score was positively associated with IEAA at years 15 (P = 0.016) and 20 (P = 0.016) and EEAA at year 20 (P = 0.040) in cross-sectional analysis. IEAA at year 20 was significantly associated with incident MetS at year 30 (OR = 1.05 [95% CI 1.01, 1.10], P = 0.028). Conclusions: To our knowledge, this is the first report of the longitudinal association between epigenetic age acceleration and MetS. These findings suggest that a higher MetS severity score is associated with accelerated epigenetic aging and such aging may play a role in the development of metabolic disorders, potentially serving as a useful biomarker of and early detection tool for future MetS.

KW - CARDIA

KW - DNA methylation

KW - Epigenetic age acceleration

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85075075814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075075814&partnerID=8YFLogxK

U2 - 10.1186/s13148-019-0767-1

DO - 10.1186/s13148-019-0767-1

M3 - Article

C2 - 31730017

AN - SCOPUS:85075075814

VL - 11

JO - Clinical Epigenetics

JF - Clinical Epigenetics

SN - 1868-7075

IS - 1

M1 - 160

ER -